[1] |
Cox SN, Serino G, Sallustio F, et al. Altered monocyte expression and expansion of non-classical monocyte subset in IgA nephropathy patients [J]. Nephrol Dial Transplant, 2015, 30(7): 1122-1232.
|
[2] |
董玉,尚顺来,李清刚,等. 来氟米特联合甲泼尼龙治疗IgA肾病的疗效观察 [J/CD]. 中华肾病研究电子杂志,2020, 9(3): 102-106.
|
[3] |
Yuan Y, Wang Q, Ni Z, et al. Long-term kidney survival analyses in IgA nephropathy patients under steroids therapy: a case control study [J]. J Transl Med, 2015, 13: 186.
|
[4] |
Liu L, Yang Y, Yu D. Identification of key miRNAs and their targets in peripheral blood mononuclear cells of IgA nephropathy using bioinformatics analysis [J]. Medicine (Baltimore), 2021, 100(26): e26495.
|
[5] |
Floege J, Eitner F. Immune modulating therapy for IgA nephropathy: rationale and evidence [J]. Semin Nephrol, 2008, 28(1): 38-47.
|
[6] |
Liu P, Lassen E, Nair V, et al. Transcriptomic and proteomic profiling provides insight into mesangial cell function in IgA nephropathy [J]. J Am Soc Nephrol, 2017, 28(10): 2961-2972.
|
[7] |
Cox SN, Sallustio F, Serino G, et al. Altered modulation of WNT-beta-catenin and PI3K/Akt pathways in IgA nephropathy [J]. Kidney Int, 2010, 78(4): 396-407.
|
[8] |
Tamouza H, Chemouny JM, Raskova Kafkova L, et al. The IgA1 immune complex-mediated activation of the MAPK/ERK kinase pathway in mesangial cells is associated with glomerular damage in IgA nephropathy [J]. Kidney Int, 2012, 82(12): 1284-1296.
|
[9] |
Lee J, An JN, Hwang JH, et al. p38 MAPK activity is associated with the histological degree of interstitial fibrosis in IgA nephropathy patients [J]. PLoS One, 2019, 14(3): e0213981.
|
[10] |
Yiu WH, Chan KW, Chan LYY, et al. Spleen tyrosine kinase inhibition ameliorates tubular inflammation in IgA nephropathy [J]. Front Physiol, 2021, 12: 650888.
|
[11] |
Chen H, Du Y, Li Y, et al. Jixuecao (Herba Centellae Asiaticae) alleviates mesangial cell proliferation in IgA nephropathy by inducing mitofusin 2 expression [J]. J Tradit Chin Med, 2019, 39(3): 346-355.
|
[12] |
Xiao L, Zhu X, Yang S, et al. Rap1 ameliorates renal tubular injury in diabetic nephropathy [J]. Diabetes, 2014, 63(4): 1366-1380.
|
[13] |
Lai KN. Pathogenesis of IgA nephropathy [J]. Nat Rev Nephrol, 2012, 8(5): 275-283.
|
[14] |
Ricardo SD, van Goor H, Eddy AA. Macrophage diversity in renal injury and repair [J]. J Clin Invest, 2008, 118(11): 3522-3530.
|
[15] |
Ikezumi Y, Suzuki T, Karasawa T, et al. Identification of alternatively activated macrophages in new-onset paediatric and adult immunoglobulin A nephropathy: potential role in mesangial matrix expansion [J]. Histopathology, 2011, 58(2): 198-210.
|
[16] |
Li J, Liu CH, Gao B, et al. Clinical-pathologic significance of CD163 positive macrophage in IgA nephropathy patients with crescents [J]. Int J Clin Exp Med, 2015, 8(6): 9299-9305.
|
[17] |
Kim J, Choi SE, Lee KH, et al. Tubulointerstitial infiltration of M2 macrophages in Henoch-Schonlein purpura nephritis indicates the presence of glomerular crescents and bad clinical parameters [J]. Biomed Res Int, 2019, 2019: 8579619.
|
[18] |
Watanabe T, Kawachi H, Ikezumi Y, et al. Glomerular CD8+ cells predict progression of childhood IgA nephropathy [J]. Pediatr Nephrol, 2001, 16(7): 561-567.
|
[19] |
Lai KN. Neutrophils in IgA nephropathy [J]. Nephrology, 1996, 2 (S1): S7-S11.
|